A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).

Ticiana A LealMarina N SharifiNancy ChanRobert WesolowskiAnita A TurkJustine Y BruceRuth M O'ReganJens EickhoffLisa M BarroilhetJyoti MalhotraJanice MehnertEugenia GirdaElizabeth WileyNatalie SchmitzShannon AndrewsGlenn LiuKari B Wisinski

Published in: Cancer medicine (2022)

on days 1, 8, 15 of 21-day cycles. This regimen is associated with significant myelosuppression, and in addition to maximizing supportive care, modification of the chemotherapy component would be a consideration for further development of this combination with the schedules investigated in this study.

Keyphrases

healthcare
randomized controlled trial
high resolution
quality improvement
mass spectrometry
study protocol
atomic force microscopy